https://scholars.lib.ntu.edu.tw/handle/123456789/568407
標題: | Predicting hepatitis B virus (HBV) surface antigen seroclearance in HBV e antigen-negative patients with chronic hepatitis B: External validation of a scoring system | 作者: | Liu J. TAI-CHUNG TSENG Yang H.-I. Lee M.-H. Batrla-Utermann R. Jen C.-L. Lu S.-N. Wang L.-Y. You S.-L. PEI-JER CHEN Chen C.-J. JIA-HORNG KAO |
公開日期: | 2015 | 出版社: | Oxford University Press | 卷: | 211 | 期: | 10 | 起(迄)頁: | 1566-1573 | 來源出版物: | Journal of Infectious Diseases | 摘要: | Background. Hepatitis B virus (HBV) surface antigen (HBsAg) seroclearance is the ultimate serological end point in chronic hepatitis B. This study aimed to develop and validate a prediction score for spontaneous HBsAg seroclearance in HBV e antigen (HBeAg)-negative patients with chronic hepatitis B due to HBV genotype B or C. Methods. The development cohort included 2491 untreated participants from the community-based REVEAL-HBV study, who were HBeAg negative, anti-hepatitis C virus negative, and cirrhosis free. The independent validation cohort consisted of 1934 hospital-based individuals from the National Taiwan University Hospital. Clinical markers included in the model were age and serum HBV DNA and HBsAg levels. Cox proportional hazards regression models were used to create the prediction model. Results. A prediction score ranging from 0 to 27 was developed. Predicted probabilities of 5-and 10-year HBsAg seroclearance ranged from 0.95% to 30.49% and from 2.58% to 62.52%, respectively. When applied to the independent validation cohort, the areas under the receiver operating characteristic curves for the 5-and 10-year prediction of HBsAg seroclearance in the validation cohort were 0.82 (95% confidence interval [CI],. 76-.88) and 0.74 (95% CI,. 70-.78). Model fit was still adequate, according to Hosmer-Lemeshow goodness of fit tests. Conclusions. A clinically applicable prediction score for HBsAg seroclearance was developed and externally validated. This model can assist clinicians in further stratifying risk groups. ? 2014 The Author. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84929657961&doi=10.1093%2finfdis%2fjiu659&partnerID=40&md5=762f628e1f3de7c0d591f08f890361fe https://scholars.lib.ntu.edu.tw/handle/123456789/568407 |
ISSN: | 0022-1899 | DOI: | 10.1093/infdis/jiu659 | SDG/關鍵字: | hepatitis B surface antigen; hepatitis B(e) antigen; hepatitis C antibody; virus DNA; hepatitis B surface antigen; hepatitis B(e) antigen; adult; age distribution; antigen detection; Article; chronic hepatitis B; cohort analysis; controlled study; female; Hepatitis B virus genotype B; Hepatitis B virus genotype C; human; liver cirrhosis; major clinical study; male; middle aged; plasma clearance; priority journal; receiver operating characteristic; risk assessment; scoring system; Taiwan; university hospital; validation process; virus load; aged; blood; classification; genetics; genotype; Hepatitis B virus; Hepatitis B, Chronic; prognosis; severity of illness index; validation study; virology; Adult; Aged; Cohort Studies; DNA, Viral; Female; Genotype; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Prognosis; Severity of Illness Index; Taiwan |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。